Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

Eur J Heart Fail · 2025 · PMC12260315 · PMID 40069106

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a negative trendno p-value reported

A negative trend can be already seen in the percentages of new CVD treatment over the total approval by FDA in the latest decades: between 2000 and 2017, in fact, the approved CVD therapies over the total of the new approvals by FDA declined from 9.09% to 5.29%. 166 Industry‐funded development research will just focus elsewhere if the trend continues.

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.